Discrete choice experiments: An overview of experience to date in haemophilia

Abstract

The patient voice is an important consideration in the availability and choice of pharmaceuticals – however, how to capture this complex area and apply it formally within regulation, health technology assessment and reimbursement remains subject to ongoing debate. Patient preference studies such as discrete choice experiments (DCEs) are being utilised more frequently in healthcare and it is anticipated that patient preference data will be incorporated more frequently into regulatory submissions moving forward.

Keywords

• discrete choice experiment
• gene therapy
• haemophilia
• patient preference
• pharmaceutical
• review